Drugs / NOV-205
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00372983 | Aug 2006 → Dec 2007 | chronic hepatitis C virus infection | Cellectar Biosciences, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01058512 | Mar → Dec 2010 | hepatitis C virus infection | Cellectar Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NOV-205 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00372983 ↗ |
| Route | Subcutaneous | “30 mg NOV-205 daily subcutaneous administration for 49 days” NCT01058512 ↗ |